Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho
May 15, 2024 5:18 AM EDTMizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining a Buy rating.
The analyst comments "1Q24 was strong, with Zoryve (Cream + Foam) beating our above-Consensus forecasts driven by significantly better-than-expected gross-to-nets (GtN),... More
